ex vivo-expanded her2-specific t cells
Cell therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2003 (NCT00228358)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
Tumor antigens immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ex vivo-expanded her2-specific t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01219907 | Phase 1 | Jun 1, 2012 | National Cancer Institute (NCI), University of Washington |
| NCT00791037 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2008 | National Cancer Institute (NCI), University of Washington |
| NCT00228358 | Phase 1 | Jun 1, 2003 | National Cancer Institute (NCI), University of Washington |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 2003 |
| University of Washington | Academic/Hospital | 3 | 3 | 2 | 2003 |
2 organizations
Page 1 / 1